Association of human myxovirus resistance protein A with severity of COVID-19.
COVID-19
Human myxovirus resistance protein A
MxA
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 Sep 2022
28 Sep 2022
Historique:
received:
20
05
2022
accepted:
21
09
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
1
10
2022
Statut:
epublish
Résumé
In this retrospective cohort study, we explored the correlation of blood human myxovirus resistance protein A (MxA) level with severity of disease in hospitalized COVID-19 patients. All 304 patients admitted for COVID-19 in our hospital until 30th of April 2021 were included in this study. MxA was measured from peripheral blood samples in 268 cases. Patients were divided into groups based on their level of MxA on admission. We studied baseline characteristics and severity of disease on admission based on clinical parameters and inflammatory biomarker levels in each group. Severity of disease during hospitalization was determined by the applied level of respiratory support, by the usage of corticosteroids and by the duration of hospitalization. Higher MxA levels on admission were associated with a shorter duration of symptoms before admission, and with more severe disease. Adjusted Odds Ratios for any respiratory support were 9.92 (95%CI 2.11-46.58; p = 0.004) in patients with MxA between 400 μg/L and 799 μg/L (p = 0.004) and 20.08 (95%CI 4.51-89.44; p < 0.001) in patients with MxA ≥ 800 μg/L in comparison with patients with initial MxA < 400 μg/L. The usage of corticosteroids was significantly higher in the high-MxA group (77%) in comparison with the intermediate-MxA group (62%, p = 0.013) and low-MxA group (47%, p < 0.001). Higher initial levels of MxA were associated with more severe COVID-19. MxA may be a helpful additional biomarker to predict the severity of the disease.
Sections du résumé
BACKGROUND
BACKGROUND
In this retrospective cohort study, we explored the correlation of blood human myxovirus resistance protein A (MxA) level with severity of disease in hospitalized COVID-19 patients.
METHODS
METHODS
All 304 patients admitted for COVID-19 in our hospital until 30th of April 2021 were included in this study. MxA was measured from peripheral blood samples in 268 cases. Patients were divided into groups based on their level of MxA on admission. We studied baseline characteristics and severity of disease on admission based on clinical parameters and inflammatory biomarker levels in each group. Severity of disease during hospitalization was determined by the applied level of respiratory support, by the usage of corticosteroids and by the duration of hospitalization.
RESULTS
RESULTS
Higher MxA levels on admission were associated with a shorter duration of symptoms before admission, and with more severe disease. Adjusted Odds Ratios for any respiratory support were 9.92 (95%CI 2.11-46.58; p = 0.004) in patients with MxA between 400 μg/L and 799 μg/L (p = 0.004) and 20.08 (95%CI 4.51-89.44; p < 0.001) in patients with MxA ≥ 800 μg/L in comparison with patients with initial MxA < 400 μg/L. The usage of corticosteroids was significantly higher in the high-MxA group (77%) in comparison with the intermediate-MxA group (62%, p = 0.013) and low-MxA group (47%, p < 0.001).
CONCLUSIONS
CONCLUSIONS
Higher initial levels of MxA were associated with more severe COVID-19. MxA may be a helpful additional biomarker to predict the severity of the disease.
Identifiants
pubmed: 36171547
doi: 10.1186/s12879-022-07753-0
pii: 10.1186/s12879-022-07753-0
pmc: PMC9517979
doi:
Substances chimiques
Biomarkers
0
Myxovirus Resistance Proteins
0
Staphylococcal Protein A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
755Informations de copyright
© 2022. The Author(s).
Références
Pediatr Res. 1997 May;41(5):647-50
pubmed: 9128286
Pediatrics. 2015 Apr;135(4):e985-93
pubmed: 25802344
Immun Inflamm Dis. 2022 Apr;10(4):e609
pubmed: 35349755
Nat Immunol. 2021 Jan;22(1):32-40
pubmed: 33277638
Ann Med. 2021 Dec;53(1):410-412
pubmed: 33305624
J Med Virol. 2001 Oct;65(2):301-8
pubmed: 11536237
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
J Clin Virol. 2015 Jan;62:8-13
pubmed: 25542463
Microorganisms. 2022 Jan 14;10(1):
pubmed: 35056625
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Nat Rev Immunol. 2020 Jul;20(7):397-398
pubmed: 32457522
J Infect. 2021 May;82(5):186-230
pubmed: 33307140
Clin Chem. 2019 Jun;65(6):739-750
pubmed: 30593466
J Immunol. 1993 Mar 1;150(5):1715-26
pubmed: 7679692
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
J Virol. 2007 Jul;81(14):7776-85
pubmed: 17494065
Sci Adv. 2021 Nov 26;7(48):eabj5629
pubmed: 34826237
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Am J Pathol. 2020 Sep;190(9):1881-1887
pubmed: 32628931
PLoS One. 2013;8(3):e59302
pubmed: 23555014
Nature. 2022 Mar;603(7899):145-151
pubmed: 35045565
J Infect. 2017 Apr;74(4):385-392
pubmed: 28077283
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Clin Microbiol Rev. 2021 May 12;34(3):
pubmed: 33980688
J Interferon Cytokine Res. 2011 Jan;31(1):79-87
pubmed: 21166595